Asarina is a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Its product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With a new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists), it is aiming to deliver a new generation of safe, efficacious drugs for neurological conditions ranging from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatment